AKT1 and neoplasm: On this basis, it was suggested that inactivation of hnRNPM or reversion of disease-relevant splicing events regulated by this RBP could be exploited to increase the efficacy of inhibitors of the PI3K/AKT/mTOR pathway in this tumor type [142].